Semaglutide in STRIDE Trial Significantly Improves Quality of Life and Physical Function
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
Abstract
Semaglutide significantly improved quality of life (EQ-5D index: 0.71 to 0.79, p<0.001) and physical function in patients, especially with ≥5% weight loss.